Clinical Trials

20 enrolled

Lymphoma, Mantle-Cell

NCT06634589 2026-04-15

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

80 enrolled

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT06090539 2026-04-14

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

308 enrolled

Phase 1 Not yet recruiting

Lymphoma, Non-Hodgkin

NCT07528352 2026-04-14

REBEL

12 enrolled

Phase 1 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07444710 2026-04-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

16 enrolled

Ann Arbor Stage II Mantle Cell Lymphoma

NCT05798156 2026-04-08

R-Pola-Glo

125 enrolled

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04408638 2026-04-07

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

270 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03533283 2026-04-06

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

211 enrolled

Lymphoma, Non-Hodgkin

NCT03075696 2026-04-03

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

940 enrolled 2 FDA

Lymphoma, Non-Hodgkin

NCT05533775 2026-04-03

iMATRIX GLO

65 enrolled

Recurrence

NCT06084936 2026-04-02

GLOBRYTE

Phase 3 Recruiting

182 enrolled

Lymphoma

NCT06624085 2026-04-02

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

50 enrolled

Lymphoma

NCT06806033 2026-03-31

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

100 enrolled

Phase 2 Not yet recruiting

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07502872 2026-03-31

TPG

30 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05896163 2026-03-27

MAPtivate-6

30 enrolled

Phase 1 Active not recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06192888 2026-03-27

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

39 enrolled

Lymphoma, Mantle-Cell

NCT05169515 2026-03-19

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

121 enrolled

Lymphoma, Non-Hodgkin

NCT04889716 2026-03-18

CAR-T Followed by Bispecific Antibodies

42 enrolled

Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT07480850 2026-03-18

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

40 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04703686 2026-03-16

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Phase 2 Completed

67 enrolled

Lymphoma, Mantle-Cell

NCT05783596 2026-03-16

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

47 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

200 enrolled

Lymphoma, B-Cell

NCT07460362 2026-03-10

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

43 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

41 enrolled

Phase 2 Not yet recruiting

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT07453095 2026-03-05

Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

41 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT04231877 2026-03-03

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

56 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04077723 2026-03-02

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

498 enrolled

Lymphoma, Non-Hodgkin

NCT05861050 2026-02-19

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

50 enrolled

Lymphoma, Mantle-Cell

NCT04980222 2026-02-17

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

46 enrolled

Lymphoma

NCT06558604 2026-02-11

GLOASIS

100 enrolled

Lymphoma, Mantle-Cell

NCT06393738 2026-02-10

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

255 enrolled

Phase EARLY_PHASE1 Recruiting

Immunoblastic Lymphadenopathy, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT04161248 2026-02-02

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

18 enrolled

Lymphoma, B-Cell

NCT06357676 2026-01-30

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

27 enrolled